On Wednesday, Eli Lilly and Company announced that a mid-stage trial for its experimental combination obesity regimen—pairing the amylin-targeting drug eloralintide with its established blockbuster tirzepatide—achieved weight loss of up … Read More
Persistent foodborne parasite outbreaks linked to fresh produce have triggered a sharp contraction in customer traffic across fast-casual salad chains. Consumers are actively avoiding leafy greens due to ongoing cyclospora … Read More
Healthcare provider Humana (NYSE: HUM) topped Wall Street expectations in its quarterly earnings report, posting solid revenue growth while maintaining its full-year 2026 adjusted profit outlook of at least $9 … Read More
Senate Minority Leader Mitch McConnell remains un-cleared by medical professionals to return to work following a physical fall, according to an official statement shared by his office. The update comes … Read More
The Centers for Disease Control and Prevention confirmed that a massive cyclospora outbreak now spans nine states, adding Illinois, Kansas, Oklahoma, and Pennsylvania to a list that already included Indiana, … Read More
Health and Human Services Secretary Robert F. Kennedy Jr. announced on July 21, 2026, that the nationwide cyclosporiasis outbreak is now considered “under control.” While the administration pivots to containment, … Read More
Taco Bell is expected to recover from a recent health safety scare linked to a cyclosporiasis outbreak, according to market analysts monitoring the restaurant industry. While the Centers for Disease … Read More
Vivani Medical’s GLP-1 Implant Strategy Targets Long-Term Weight Management Vivani Medical (NASDAQ: VVM) is developing a miniature, subcutaneous implant designed to deliver sustained, steady-state doses of semaglutide. By targeting the … Read More
Medicare will begin covering obesity treatments including GLP-1 drugs like Eli Lilly (NYSE: LLY)‘s Zepbound and Novo Nordisk (NASDAQ: NVO)‘s Wegovy on July 1, 2026, marking the first federal expansion … Read More
As of June 2026, the global pharmaceutical sector is intensifying efforts to challenge the market dominance of Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in the GLP-1 obesity … Read More
